drugset / Trial / NCT03062956

A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491

NCT03062956

Phase 1 Completed 64 enrolled MyoKardia, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

Up to 72 healthy volunteers will be given a single dose of MYK-491 or placebo and be monitored for safety and tolerability over a 7 day period.

Timeline

Start
2017-01-16
Primary completion
2017-11-28
Completion
2017-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Danicamtiv Small molecule Oral